Listen to Article

The old proverb, “It’s an ill wind that blows nobody any good” is especially true regarding COVID-19 because the virus that continues to play havoc with the world also continues to be very, very good for Big Pharma. 

The “Operation Warped Speed” vaccines funded by governments and sold back to them by the drug dealers to allegedly protect against the coronavirus are already among the best-selling pharmaceuticals of all time. 

And, as the trendline shows, with deals in place to keep supplying the vaccines with booster shots galore through 2023, the financial tide will keep coming in. Indeed, in our 11 May article, “DRUG COMPANIES CASHING IN ON COVID,” we detailed how Big Pharma sees the need for the COVID vax as an ongoing “revenue stream,” and, thus, is in no hurry at all to see it end. 

Did You Know...?

The big-money vaccine deals are not highly publicized. In sales through next year, Pfizer and Moderna expect to rack up $70 billion and more than $27 billion, respectively. (We reported on the amount of profits amassed by Moderna in our 2 March article, “MODERNA EXPECTS TO REAP $18.4 BILLION FROM VACCINE SALES.”)

For example, as reported by the Wall Street Journal last Thursday, Pfizer and BioNTech will be supplying the EU with up to 18 billion doses of vaccine through 2023, and Canada will receive up to 125 million doses. Australia, Switzerland, and Israel have deals to get Moderna’s vaccine through next year, and Switzerland has options for 2023. The U.S. will receive 300 million doses each from Pfizer and Moderna by 31 July, with options to purchase more. 

These countries are making sure they have sufficient supplies to vaccinate their populations against emerging variants of the virus. Lower-income, developing countries would also like to be well-supplied with vaccines, but they don’t have the same resources. 

Rich vs. Poor

The gap between rich and poor is evident: some two dozen rich nations plus the EU have together purchased, thus far, some six billion doses, whereas the rest of the world combined has purchased roughly half that number. 

Covax, a global health initiative set up to supply vaccines to lower- and middle-income countries, will be receiving 34 million doses from Moderna by the last quarter of this year, with an option to buy 466 million next year.

That won’t close the gap, however, and poorer countries will depend on richer ones to share their supplies. Poorer nations may also be expected to make deals with China and Russia, who are eager to supply vaccines from their own producers. 

TRENDPOST: How much money are the big drug dealers making, and how much is it costing taxpayers? Buried in the Wall Street Journal article is the fact that “neither the countries nor the companies disclosed the terms of the recent deals.” And, as we have reported, Pfizer gave President Biden a $1 million “thank you” to help celebrate his inauguration this past January. 

What fuels the clamor for vaccines, of course, is the world’s great fear of this virus and acceptance of vaccination as the remedy, with any notions to the contrary, such as skepticism about risk statistics or questions about the safety of the vaccines, downplayed or suppressed. As Dr. Paul Craig Roberts detailed in his article in the 25 May Trends Journal, “AMERICA’S PUBLIC HEALTH SYSTEM IS UTTERLY CORRUPT.”

Support the Trends Journal with these great products

  1. […] However, despite the revenue boosts, the profitability of the COVID War for largely-retail concerns like CVS pales in comparison to that enjoyed by the true Drug Lords, the producers of the vaccines; see our 8 June 2021 article, "DRUG LORDS' VAX BOOM BOOMING." […]

  2. […] Or that the vax makers have done so very well financially, and expect to continue to do so?See "DRUG LORDS' VAX BOOM BOOMING" (8 Jun […]

  3. […] and away, is and always has been Pfizer; see "DRUG COMPANIES CASHING IN ON COVID" (11 May 2021) and "DRUG LORDS' VAX BOOM BOOMING" (8 Jun […]

Leave a reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

©2022 The Trends Journal

Log in with your credentials

Forgot your details?